UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **May 30, 2013**

Biogen Idec Inc.

(Exact name of registrant as specified in its charter)

Delaware	**0-19311**	**33-0112644**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

133 Boston Post Road, Weston, Massachusetts 02493
(Address of principal executive offices; Zip Code)

Registrant's telephone number, including area code: **(781) 464-2000**

Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

Biogen Idec Inc. (Biogen Idec) is seeking to launch TECFIDERA™ in the European Union (EU) with patent and regulatory data protection. On May 29, 2013, Biogen Idec was granted a European patent that extends until 2028 and covers the expected EU TECFIDERA label dose of 480 mg. Biogen Idec believes TECFIDERA is also entitled to regulatory data protection in the EU and is working to make TECFIDERA'S regulatory data protection clearer to all parties prior to launch. This is expected to delay the launch of TECFIDERA in the EU until the second half of 2013.

Attached hereto as Exhibit 99.1 are slides from an investor presentation that Biogen Idec plans to present at the Deutsche Bank 38th Annual dbAccess Health Care Conference on May 30, 2013.

Limitation on Incorporation by Reference. The information furnished in this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such a filing.

Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in the presentation attached as an exhibit hereto, the presentation contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary notes above and in the presentation regarding these forward-looking statements.

Item 9.01. Financial Statements and Exhibits.

The exhibit listed on the Exhibit Index immediately preceding such exhibit is filed as part of this Current Report on Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOGEN IDEC INC.

By: /s/ Robert A. Licht
Robert A. Licht
Senior Vice President

Date: May 30, 2013

EXHIBIT INDEX

Exhibit Number	Description
99.1	Investor Presentation

biogen idec



BIOGEN IDEC

38TH ANNUAL dbACCESS HEALTH CARE CONFERENCE

BOSTON, MA

MAY 30, 2013

Forward-Looking Statements

This presentation contains forward-looking statements, including statements about our growth prospects, regulatory filings and agency actions, product launch plans and the anticipated timing thereof, our intellectual property, data and other proprietary rights, the anticipated development of and data readouts from programs in our clinical pipeline, and the development, commercialization and therapeutic effect of new and potential treatments. These forward-looking statements may be accompanied by such words as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "potential," "project," "target," "will" and other words and terms of similar meaning. You should not place undue reliance on these statements.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including our dependence on our three principal products, AVONEX, TYSABRI and RITUXAN, the importance of TYSABRI's sales growth, uncertainty of success in executing our commercial launch of TECFIDERA, uncertainty of success in commercializing and developing other products, product competition, the occurrence of adverse safety events with our products, changes in the availability of reimbursement for our products, adverse market and economic conditions, our dependence on collaborations and other third parties over which we may not always have full control, problems with our manufacturing processes and our reliance on third parties, failure to comply with government regulation, our ability to protect our intellectual property, data and other proprietary rights and have sufficient rights to market our products together with the cost of doing so, the risks of doing business internationally, failure to manage our growth and execute our growth initiatives, charges and other costs relating to our properties, fluctuations in our effective tax rate, our ability to attract and retain qualified personnel, product liability claims, fluctuations in our operating results, the market, interest and credit risks associated with our portfolio of marketable securities, environmental risks, change of control provisions in our collaborations and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the SEC.

These statements are based on our current beliefs and expectations and speak only as of the date of this presentation. We do not undertake any obligation to publicly update any forward-looking statements.

biogen idec

Consistently Strong Financial Performance







Note: a reconciliation of our GAAP to non-GAAP EPS and free cash flow appears at the end of this presentation.

biogen idec

Pillars of Near and Long-term Growth

Pillars of Near and Long-term Growth



Core Products:
Provide Sustainable Revenue Stream

AVONEX (interferon beta-1a)

A leading worldwide therapy for multiple sclerosis

TYSABRI (natalizumab)



Powerful multiple sclerosis therapy

Tecfidera (dimethyl fumarate) delayed-release capsules

Effective & convenient oral therapy for multiple sclerosis

fampyra 10 mg prolonged-release tablets fampridine

-- Ex US --

First treatment indicated to improve walking in multiple sclerosis

Rituxan Rituximab



Standard of care for NHL and CLL

Includes Industry-leading MS Franchise

biogen idec

AVONEX: Maintaining a leading position in first-line MS use

AVONEX
Revenues **($B)**



GAINING SHARE WITHIN THE INJECTABLE CLASS

- One of the most prescribed treatments for relapsing forms of MS worldwide
- A treatment you can start and stay on
- Maintaining leading position within the interferon class
- Convenience is key differentiator within injectable segment

AVONEX PEN®

AVOSTARTGRIP™

biogen idec

TYSABRI:
Solid growth trajectory driven by powerful efficacy

TYSABRI
In Market Sales **($M)**

HIGH EFFICACY SEGMENT LEADER

- A compelling treatment option that may be considered early at the first sign of progression
  - Proven to reduce flare-ups and slow physical disability progression
  - Reduces ARR by 68% and EDSS by 42- 54%
- JCV assay is changing the treatment paradigm
  - Earlier adoption seen in JCV ab (-) patient population
  - Majority of the patients who are starting TYSABRI treatment are JCV ab (-)
  - Retention rates are generally higher in the JCV ab (-) patient population

biogen idec

TYSABRI in SPMS: High Unmet Medical Need

- SPMS is a large portion of the MS market
- No effective therapies for SPMS
- Trends towards improved ambulation in patients with SPMS seen in two prior TYSABRI trials

ASCEND Trial Overview

- An investigation of whether TYSABRI treatment slows the accumulation of disability not related to relapses in patients with SPMS
- Primary endpoint: the proportion of subjects experiencing confirmed progression of disability as measured by a composite endpoint
- FDA special protocol assessment (SPA) obtained with accepted regulatory endpoint
- Data readout expected 2015

biogen idec

TECFIDERA (dimethyl fumarate): Providing a strong oral option for MS treatment

Anticipate broad appeal to a large segment of prescribing neurologists and MS patients

FDA Approved March 27, 2013

- Strong efficacy
- Favorable safety profile
- Convenience of oral administration
- High physician awareness

Improved IP offers protection until 2028

biogen idec

*Under Active Review with EMA

TECFIDERA US Launch Underway

US Launch off to a Great Start

- Pleased with the speed and quality of the execution by the US Commercial organization
- Encouraged by the early signs with both high patient and physician interest
- New starts coming from both naïve to therapy and patient switches
- Expect to be the leading oral MS therapy over time

Tecfidera® (dimethyl fumarate)

biogen idec

TECFIDERA Europe Update

EC Approval Now Expected 2H 2013

- European TECFIDERA patent covering the 480mg dose until 2028 granted yesterday
- Biogen Idec working to make TECFIDERA Regulatory Data Protection clearer to all parties
- Goal is to launch with the strongest package in place
- Primary commercial launch expected to occur in Germany 2H 2013
- Additional European country launches expected to follow later
- Delay is prudent to preserve value over the long term

biogen idec

Pillars of Near and Long-term Growth

biogen idec

Pillars of Near and Long-term Growth

biogen idec

PLEGRIDY:
Interferon Candidate with a strong potential

MS therapies	Administration	Injections per year
PLEGRIDY	sub-Q	No more than 26
AVONEX	IM	52
Rebif®	sub-Q	156
Betaseron®	sub-Q	182
Extavia®	sub-Q	182
Copaxone®	sub-Q	365

Note: sub-Q = subcutaneous injection, IM = Intramuscular injection.

FDA Filing Announced May 2013
Plan to File with EMA in Coming Weeks

POTENTIAL TO PROVIDE STRONG EFFICACY & COMPELLING CONVENIENCE

- Positive Phase III (ADVANCE) trial results showed potential for every two and four week dosing to significantly reduce relapses and disability progression with a favorable safety and tolerability profile
- Potential to grow market share within the injectable segment
- Potential to reduce current treatment burden

biogen idec

PLEGRIDY is still under investigation and not commercially available

ELOCTATE (rFVIIIFc): Potential first long-lasting treatment for Hemophilia A



- ELOCTATE has **1.5-fold fold longer half-life**

Hypothetical for illustrative purposes only based on data seen in Valentino et al, The Journal of Thrombosis and Haemostasis (JTH), March 2012 and the weekly prophylaxis arm in the A-Long study. No head-to-head studies have been conducted.

- The extended half-life of ELOCTATE may allow for **once to twice weekly** prophylactic treatment
- Potential for prophylactic patients to **reduce** their injections by **50 to 100** per year
- Potential for episodic patients to dose once weekly prophylactically and significantly reduce their bleeding episodes with the same number of injections per year
- Zero inhibitors seen in clinical trial
- Announced in May 2013 our BLA submission was accepted by FDA; standard review

biogen idec

sobi
SWEDISH ORPHAN BIOVITRUM

*Registered trademark of Baxter International

ELOCTATE is still under investigation and not commercially available

ALPROLIX (rFIXFc): Potential first long-lasting treatment for Hemophilia B

- ALPROLIX showed a **2.4-fold longer half-life** compared to BeneFIX® in the B-LONG study
- Prophylactic dosing every **1-2 weeks** resulted in **low bleeding rates**
- Potential to have major impact on adoption of prophylaxis
- Zero inhibitors seen in clinical studies
- Announced in March 2013 our BLA submission was accepted by FDA; standard review

sobi
SWEDISH ORPHAN BIOVITRUM

biogen idec

ALPROLIX is still under investigation and not commercially available

Pillars of Near and Long-term Growth

biogen idec

Pillars of Near and Long-term Growth

biogen idec

Pipeline



biogen idec

Pipeline Hallmarks

Better Drug Discovery

- Focus on targets with a well understood biology
- Use biomarkers and imaging to determine if we are hitting the target in tissue of interest
- Better tools to determine the best treatment for each patient

Example: STX-100



Inhibiting αvβ6 keeps TGFβ inactive, preventing fibrosis

- STX-100 is a humanized monoclonal targeting integrin αvβ6, which selectively modulates a central pathway (TGFβ) in fibrosis, including IPF

biogen idec

A Passion for Innovative Science

R&D Vision:
Create the Best Science Driven R&D Pipeline

- Approaches to understand the biology of devastating diseases
- Collaboration with top tier academic centers
  - Novel ALS consortium of eminent neuroscientists focused on understanding the biology of ALS including:
    - Pietro De Camilli, M.D.
    - J. Wade Harper, Ph.D.
    - Christopher E. Henderson, Ph.D.
    - Arthur L. Horwich, M.D.
    - Lee L. Rubin, Ph.D.
    - Marc Tessier-Lavigne, Ph.D.
  - Harvard Interactome Project established to understand human protein-protein interactions and define novel pathways for drug target identification

DROSOPHILA INTERACTOME COURTESY OF SPYROS ARTAVANIS-TSAKONAS, Ph.D.

Academic Collaborations



biogen idec

Biogen Idec: A Bright Future

- Strong near-term growth prospects driven by our **core business**
- Entering into an era of significant long-term growth driven by multiple potential **new product launches**
- Building an **innovative pipeline** to sustain longer-term value creation



biogen idec

GAAP to Non-GAAP Reconciliation

Condensed Consolidated Statements of Income – Operating Basis (unaudited, $ in millions, except per share amounts)	FY 2007	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012
GAAP diluted EPS	**$ 1.99**	**$ 2.65**	**$ 3.35**	**$ 3.94**	**$5.04**	**$5.76**
Adjustment to net income attributable to Biogen Idec Inc. (see below)	$ 0.75	$ 1.01	$ 0.77	$ 1.21	$0.86	$0.77
Effect of the adoption of a new accounting standard which requires allocation of income to certain holders of equity and debt instruments	-	-	-	-		
Non-GAAP diluted EPS	**$ 2.74**	**$ 3.66**	**$ 4.12**	**$ 5.15**	**$5.90**	**$6.53**
GAAP Net Income Attributable to Biogen Idec Inc.	**$ 638**	**$ 783**	**$ 970**	**$ 1,005**	**$1,234**	**$1,380**
R&D – Severance and restructuring	1	1	3	1	-	9
R&D – Expenses paid by Cardiokine	-	5	8	5	-	-
SG&A – Severance and restructuring	1	4	-	6	-	-
2010 Restructuring initiatives	-	-	-	75	19	2
Amortization of intangible assets	258	333	290	209	206	194
In-process R&D (IPR&D) related to the 2003 Biogen Idec merger; the 2006 acquisitions of Conforma and Fumapharm; the 2007 acquisition of Syntonix and consolidation of Cardiokine and Neurimmune; the contingent consideration payments made in 2008 associated with the 2006 Conforma acquisition and in 2010 associated with the 2007 Syntonix acquisition, and the 2010 IPR&D charge related to the consolidation of Knopp	84	25	-	245	-	-
(Gain)/loss on sale of long lived assets	-	(9)	-	-	-	
Other income, net: Gain on sale of long lived assets	(7)	-	-	-	-	
Income tax effect primarily related to reconciling items	(66)	(82)	(97)	(116)	(62)	(53)
Stock option expense	36	26	29	33	12	8
Fair value adjustment of contingent consideration associated with 2010 Panima acquisition and 2011 purchase of Dompe's noncontrolling interst					36	27
Net income attributable to non-controlling interests: consolidation of Knopp in 2010, Cardiokine and Neurimmune in 2007 and expenses paid by Cardiokine in 2008, 2009 and 2010.	(65)	(5)	(8)	(149)	-	-
Non-GAAP Net Income Attributable to Biogen Idec Inc.	**$ 879**	**$ 1,081**	**$ 1,195**	**$ 1,315**	**$1,446**	**$1,567**

Free Cash Flow Reconciliation (unaudited, $ in millions)	FY 2007	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012
Net cash flows provided by operating activities	$ 1,019	$ 1,562	$ 1,075	$ 1,625	$1,728	$ 1,880
Purchases of property, plant and equipment (Capital Expenditures)	284	276	166	173	208	255
Free Cash Flow	**$ 735**	**$ 1,286**	**$ 909**	**$ 1,452**	**$1,520**	**$ 1,625**

Use of Non-GAAP Financial Measures

We supplement our consolidated financial statements presented on a GAAP basis by providing additional measures which may be considered "non-GAAP" financial measures under applicable SEC rules. We believe that the disclosure of these non-GAAP financial measures provides additional insight into the ongoing economics of our business and reflects how we manage our business internally, set operational goals and forms the basis of our management incentive programs. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be viewed in isolation or as a substitute for reported, or GAAP, net income attributable to Biogen Idec Inc. and diluted earnings per share.

Our "Non-GAAP net income attributable to Biogen Idec Inc." and "Non-GAAP diluted EPS" financial measures exclude the following items from GAAP net income attributable to Biogen Idec Inc. and diluted earnings per share:

1. Purchase accounting and merger-related adjustments.
We exclude certain charges related to the 2003 merger between Biogen Inc. and Idec Pharmaceuticals, Inc., certain acquisition-related items, and certain amounts in relation to the consolidation of variable interest entities for which we are the primary beneficiary. These adjustments include charges for in-process research and development, the amortization of certain acquired intangible assets and adjustments to the fair value of our contingent consideration obligations. The exclusion of these charges provides management and investors with a supplemental measure of performance which the Company believes better reflects the underlying economics of the business.

2. Stock option expense recorded in accordance with the accounting standard for share-based payments.
We believe that excluding the impact of expensing stock options better reflects the recurring economic characteristics of our business.

3. Other items.
We evaluate other items on an individual basis, and consider both the quantitative and qualitative aspects of the item, including (i) its size and nature, (ii) whether or not it relates to our ongoing business operations, and (iii) whether or not we expect it to occur as part of our normal business on a regular basis. We also include an adjustment to reflect the related tax effect of all reconciling items within our reconciliation of our GAAP to Non-GAAP net income attributable to Biogen Idec Inc.

biogen idec